Compare · CELL vs PM
CELL vs PM
Side-by-side comparison of PhenomeX Inc. (CELL) and Philip Morris International Inc (PM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and PM operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM carries a market cap of $277.88B.
- PM has hit the wire 8 times in the past 4 weeks while CELL has been quiet.
- PM has more recent analyst coverage (25 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Philip Morris International Inc
- Price
- $1.00+0.14%
- $175.69-1.46%
- Market cap
- -
- $277.88B
- 1M return
- -
- +2.67%
- 1Y return
- -
- -2.71%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest PM
- Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 2014
- Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only
- Philip Morris International to Host Webcast of Presentation at the 2026 dbAccess Global Consumer Conference
- SEC Form SD filed by Philip Morris International Inc
- Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Philip Morris International Announces Group CFO Succession
- PMI U.S. Expands Its Talent Pipeline and Welcomes New Class of Interns Across the Enterprise
- SEC Form SCHEDULE 13G filed by Philip Morris International Inc
- Director Combes Michel was granted 1,119 shares, increasing direct ownership by 11% to 11,643 units (SEC Form 4)